Prasant Chandran

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10485261/publications.pdf

Version: 2024-02-01

18	1,618	17 h-index	18
papers	citations		g-index
18	18	18	2175
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Pharmacological modulation of brain activity in a preclinical model of osteoarthritis. Neurolmage, 2013, 64, 341-355.	4.2	24
2	Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB2 receptor agonists for pain management. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2604-2608.	2.2	11
3	Default-Mode-Like Network Activation in Awake Rodents. PLoS ONE, 2011, 6, e27839.	2.5	94
4	Central and peripheral sites of action for CB ₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. British Journal of Pharmacology, 2011, 162, 428-440.	5.4	115
5	Paradigm shift in translational neuroimaging of CNS disorders. Biochemical Pharmacology, 2011, 81, 1374-1387.	4.4	27
6	Potentiation of analgesic efficacy but not side effects: Co-administration of an $\hat{l}\pm4\hat{l}^22$ neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats. Biochemical Pharmacology, 2011, 82, 967-976.	4.4	47
7	TRPV1-related modulation of spinal neuronal activity and behavior in a rat model of osteoarthritic pain. Brain Research, 2011, 1369, 158-166.	2.2	45
8	Indol-3-ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB ₂ Cannabinoid Receptor Activity. Journal of Medicinal Chemistry, 2010, 53, 295-315.	6.4	129
9	H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats. Pharmacology Biochemistry and Behavior, 2010, 95, 41-50.	2.9	84
10	Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems. Brain Research, 2010, 1354, 74-84.	2.2	36
11	Characterization of a Cannabinoid CB ₂ Receptor-Selective Agonist, A-836339 [2,2,3,3-Tetramethyl-cyclopropanecarboxylic Acid [3-(2-Methoxy-ethyl)-4,5-dimethyl-3 <i>H</i> -thiazol-(2 <i>Z</i>)-ylidene]-amide], Using in Vitro Pharmacological Assays, in Vivo Pain Models, and Pharmacological Agonist Resonance Imaging.	2.5	82
12	Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 141-151. Pharmacological modulation of movement-evoked pain in a rat model of osteoarthritis. European Journal of Pharmacology, 2009, 613, 39-45.	3.5	100
13	The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL- $1\hat{i}\pm\hat{l}^2$ knockout mice. Behavioural Brain Research, 2009, 204, 77-81.	2.2	108
14	Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain, 2009, 142, 27-35.	4.2	131
15	Indol-3-yl-tetramethylcyclopropyl Ketones: Effects of Indole Ring Substitution on CB ₂ Cannabinoid Receptor Activity. Journal of Medicinal Chemistry, 2008, 51, 1904-1912.	6.4	77
16	A-740003 [N-(1-{[(Cyanoimino)(5-quinolinylamino)) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 152 Td (methyl]amino Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1376-1385.	no}-2,2-dim 2.5	nethylpropyl)-2 375
17	Development of opioid tolerance with repeated transcutaneous electrical nerve stimulation administration. Pain, 2003, 102, 195-201.	4.2	104
18	Enhanced reduction in hyperalgesia by combined administration of clonidine and TENS. Pain, 2002, 100, 183-190.	4.2	29